Alkem Laboratories has announced its consolidated financial results for Q2 2026. The company reported a total income of ₹41,046.8 million and a profit after tax of ₹7,791.1 million. The Board has approved these results, and the review report has been submitted. The company’s performance reflects continued growth in revenue and profitability, despite a challenging global environment. Further details, including segment-wise performance, will be discussed in an upcoming investor call.
Financial Performance Overview
Alkem Laboratories announced its consolidated financial results for the quarter ended September 30, 2025 (Q2 2026). Key financial highlights include:
- Total Income: ₹41,046.8 million
- Profit Before Tax: ₹8,958.3 million
- Profit After Tax: ₹7,791.1 million
Revenue Growth
The company’s revenue from operations stood at ₹40,009.9 million for the quarter ended September 30, 2025, compared to ₹33,711.4 million in the previous quarter and ₹34,146.7 million in the corresponding quarter of the previous year.
Expenses
Total expenses for the quarter amounted to ₹32,088.5 million, which included:
- Cost of materials consumed: ₹9,055.7 million
- Employee benefits expense: ₹7,102.5 million
- Other expenses: ₹9,689.4 million
Earnings Per Share
The basic and diluted earnings per share stood at ₹63.99 for the quarter ended September 30, 2025.
Assets and Liabilities
As of September 30, 2025, the company’s total assets were valued at ₹202,874.5 million, with total equity amounting to ₹138,109.3 million.
Auditor’s Review
Deloitte Haskins & Sells LLP have conducted an independent auditor’s review and issued an unmodified report on the consolidated financial results.
Standalone Results
Alkem Laboratories also released its standalone financial results. The standalone revenue from operations was ₹25,420.3 million, and the profit after tax stood at ₹7,236.6 million.
Source: BSE
